Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Coherus Oncology, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
City of Hope Medical Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Bristol-Myers Squibb
Gene Solutions
National Cancer Institute (NCI)
Xencor, Inc.
Exelixis
Bayer
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Celgene
Xencor, Inc.
Incyte Corporation
Roswell Park Cancer Institute
AbbVie
Pfizer
AbbVie
Incyte Corporation
Incyte Corporation
Gilead Sciences
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Eli Lilly and Company
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Sichuan Huiyang Life Science and Technology Corporation
Pfizer
Swiss Cancer Institute
Inovio Pharmaceuticals
University of Kansas Medical Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Fox Chase Cancer Center
National Cancer Institute (NCI)
Angiochem Inc
INSYS Therapeutics Inc
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center